Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include SWI swissinfo.ch, BioSpace, Endpoints News and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 50d ago.
Quick answers
Why is "Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-exp" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Roche snags rights to South Korean obesity treatment SWI swissinfo.ch · 53d ago
- Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug BioSpace · 53d ago
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset Endpoints News · 53d ago
- Roche makes $2.3B bet on Hanmi’s muscle-sparing obesity asset FirstWord Pharma · 53d ago
- Hanmi Pharm shares jump 30% on Genentech obesity drug deal Investing.com · 53d ago
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy PR Newswire · 53d ago
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism Fierce Biotech · 53d ago
Topics
Related trends
Dutch cycling team to investigate claims that ‘traumatised’ riders feel ‘unsafe’: ‘I thought about harming myself’
Dutch pro team Picnic PostNL launches an independent probe after riders describe a ‘culture of fear’ that left some feeling unsafe and traumatised.
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
Roche Halts Development of Obesity Drug Candidate
Roche has halted the development of emugrobart, a muscle-preserving obesity drug candidate, following a failed interim analysis.
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.